2,7-二甲基-7H-吡咯并[2,3-d]嘧啶 | 14356-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 2,7-二甲基-7H-吡咯并[2,3-d]嘧啶
• 英文名称: 2,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 2,7-Dimethyl-7H-pyrrolo[2,3-d]pyrimidine；2,7-dimethylpyrrolo[2,3-d]pyrimidine
• CAS: 14356-75-3
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: CAPLIPOGPNGOGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES DU SPECTRE AUTISTIQUE, DE TROUBLES OBSESSIVO-COMPULSIFS ET DE TROUBLES DE L'ANXIÉTÉ
  申请人：RUGEN HOLDINGS CAYMAN LTD

  公开号：WO2018098128A1

  公开（公告）日：2018-05-31

  Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

  揭示了通过给予特定NR2B亚单位选择性NMDA（N-甲基-D-天冬氨酸）拮抗剂来治疗NMDA受体介导的疾病的方法。NMDA受体介导的疾病包括自闭症谱系障碍、强迫症和焦虑症。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100695A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME<br/>[FR] COMPOSÉS HÉTÉROARYLE UTILISÉS COMME INHIBITEURS DE NÉCROSE, COMPOSITION ET PROCÉDÉ D'UTILISATION DE CEUX-CI
  申请人：ZHANG XIAOHU

  公开号：WO2020146858A1

  公开（公告）日：2020-07-16

  The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) is shown below:

  本公开提供了Formula (I)的杂环芳基化合物，其制备方法，含有它们的药物组合物，以及它们在治疗由或与坏死相关的疾病和紊乱中的应用。Formula (I)如下所示：
• AMIDE COMPOUND
  申请人：Setoh Masaki

  公开号：US20110130384A1

  公开（公告）日：2011-06-02

  The present invention aims to provide a prophylactic or therapeutic agent for schizophrenia and the like, containing the compound of the present invention having a GPR52 agonist activity. A compound represented by the following formula (I) or a salt thereof: wherein, A is —CONH or the like, B is a hydrogen atom or a substituent, ring Cy1 is a benzene ring or the like, X 1 , X 2 and X 3 are each independently —CH═ or —N═ or the like, ring Cy2 is a carbon ring or the like, Z is a carbon atom or a nitrogen atom, L is a bond or the like, n is 1 or 2, R b is a hydrogen atom or a substituent, and ring Cy3 is a benzene ring or the like.

  本发明旨在提供一种预防或治疗精神分裂症等疾病的药物，其含有具有GPR52激动剂活性的本发明化合物。化合物的结构式如下（I）或其盐：其中，A为—CONH或类似物，B为氢原子或取代基，环Cy1为苯环或类似物，X1、X2和X3分别独立地为—CH═或—N═或类似物，环Cy2为碳环或类似物，Z为碳原子或氮原子，L为键或类似物，n为1或2，Rb为氢原子或取代基，环Cy3为苯环或类似物。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20150133427A1

  公开（公告）日：2015-05-14

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐和药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。